Holen Sie sich die Stockscreener-App
10.17
1.80%
0.18
Vorhandelsmarkt:
10.37
0.20
+1.97%
Schlusskurs vom Vortag:
$9.99
Offen:
$10.17
24-Stunden-Volumen:
616.84K
Relative Volume:
0.80
Marktkapitalisierung:
$634.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-3.0709
EPS:
-3.3117
Netto-Cashflow:
$-8.40M
1W Leistung:
+8.42%
1M Leistung:
-7.29%
6M Leistung:
-23.59%
1J Leistung:
-24.67%
1-Tages-Spanne:
$9.85
$10.52
1-Wochen-Bereich:
$9.50
$11.06
52-Wochen-Spanne:
$8.97
$30.96
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
10.17 | 634.78M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
Short Interest in Immunome, Inc. (NASDAQ:IMNM) Grows By 12.2% - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap UpShould You Buy? - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Consensus PT from Brokerages - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World
Immunome (NASDAQ:IMNM) Stock Price Down 7.1%Here's Why - MarketBeat
Immunome’s (IMNM) Outperform Rating Reaffirmed at Wedbush - Defense World
Immunome (NASDAQ:IMNM) Given "Outperform" Rating at Wedbush - MarketBeat
Immunome (NASDAQ:IMNM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire
Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Barclays PLC - Defense World
Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Hummingbird Bioscience Licenses Novel Antibodies to Immunome - The Korea Bizwire
When the Price of (IMNM) Talks, People Listen - Stock Traders Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome Awards Stock Options to Key New Hires in Strategic Talent Acquisition Move - StockTitan
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Drop in Short Interest - MarketBeat
Geode Capital Management LLC Has $17.66 Million Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Geode Capital Management LLC Increases Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Barclays PLC Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome (NASDAQ:IMNM) Shares Down 5.7%Time to Sell? - MarketBeat
State Street Corp Sells 176,768 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
State Street Corp Cuts Stock Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Wellington Management Group LLP - Defense World
Wellington Management Group LLP Has $2.06 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short Interest - Defense World
Immunome, Inc. (NASDAQ:IMNM) Short Interest Update - MarketBeat
Long Term Trading Analysis for (IMNM) - Stock Traders Daily
Immunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM) - Seeking Alpha
The Manufacturers Life Insurance Company Sells 1,437 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Point72 Asset Management L.P. Boosts Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Intech Investment Management LLC Takes $219,000 Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Janus Henderson Group PLC Purchases 324,614 Shares of Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Cerity Partners LLC Has $776,000 Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Where are the Opportunities in (IMNM) - Stock Traders Daily
Immunome Grants Stock Options to 15 New Hires in Workforce Expansion - StockTitan
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - The Bakersfield Californian
President of Immunome Picks Up 24% More Stock - Simply Wall St
Why Is Immunome Inc (NASDAQ: IMNM) Gaining? - Stocks Register
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - Defense World
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock - Investing.com India
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock By Investing.com - Investing.com Australia
Immunome Inc (IMNM) CEO Clay Siegall Increases Stake with Signif - GuruFocus.com
Insider Buying: Robert Lechleider Acquires Shares of Immunome In - GuruFocus.com
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Option Exercise |
1.05 |
42,000 |
44,100 |
61,856 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Sale |
16.01 |
14,380 |
230,224 |
47,476 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):